Business Context and Reporting Period
GE HealthCare Technologies Inc. filed a Form 8-K under Item 5.02 on May 9, 2023, reporting an executive leadership transition announced May 4, 2023. James K. (Jay) Saccaro will become Vice President and Chief Financial Officer effective June 1, 2023.
Key Financial and Corporate Metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics are reported in this filing.
- Mr. Saccaro will receive an annual base salary of $875,000, a target annual bonus opportunity of 100% of base salary, and a target annual long-term incentive award with a grant-date value of $3.8 million.
- Additional disclosed compensation includes a $1.9 million Founders Grant, a $350,000 cash sign-on payment, and a $3.5 million sign-on equity award.
- A contingent make-whole award may be provided for forfeited vested options, based on intrinsic value and capped at $3.0 million.
Material Changes Versus the Prior Comparable Period
- Mr. Saccaro will replace Helmut Zodl as Chief Financial Officer effective June 1, 2023.
- Mr. Zodl will become Global Vice President, Special Projects and TSA Separation. The filing states that his compensation arrangements will not change as a result of the transition.
Outlook, Commentary, Risks, and Unusual Items
- Mr. Saccaro previously served as Chief Financial Officer of Baxter International Inc. beginning in July 2015 and has held finance, strategy, treasury, and international operating roles.
- The 2023 long-term incentive award consists of 50% performance stock units, 25% restricted stock units, and 25% stock options, with vesting generally scheduled from 2024 through 2026.
- The Founders Grant consists of 25% restricted stock units and 75% stock options, vesting in February 2025 and February 2026.
- The sign-on cash payment is subject to repayment if Mr. Saccaro resigns on or before the one-year anniversary of payment or is terminated for cause. Similar repayment conditions apply to the cash portion of any make-whole award.
- The make-whole award is contingent on Mr. Saccaro being unable to exercise certain vested options from his prior employer because of applicable securities laws or insider-trading policies.
- The offer letter requires protective covenants and proprietary-information agreements. The full offer letter was to be filed with GE HealthCare’s Form 10-Q for the quarter ended June 30, 2023.
Important Facts for Investors to Verify
- Confirm the effective date of the CFO transition and the scope of Mr. Zodl’s TSA Separation responsibilities.
- Review the subsequently filed offer letter for the detailed terms, valuation, vesting provisions, and forfeiture conditions of the equity and cash awards.
- Assess the potential compensation expense and dilution from the stock units, performance units, and options.
- Verify whether any contingent make-whole award was ultimately granted and its final amount.
- Note that the filing does not provide financial guidance, operating results, or a quantified assessment of the transition’s expected financial impact.